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A deep brain stimulation (DBS) system delivers waves as 
electrical impulses to key brain structures, to modulate 
neural activity, to restore the balance of circuits that are 
disrupted, overcoming abnormal activity in brain deep 
regions. In 2002, invasive DBS (I-DBS) for the treatment 
of Parkinson’s disease (PD) was approved by the US 
Food and Drug Administration (FDA).1 In clinical study, 
implementing the I-DBS electrodes in the brain is an only 
way to deliver constant electrical stimulation to areas 
within the brain. DBS is used for treatment of patients 
with PD, dystonia, tremor, Tourette syndrome, intractable 
pain, epilepsy, major depression, bipolar disorder, 
obsessive–compulsive disorder, anorexia nervosa, 
Alzheimer disease. Studies verify that application of 
DBS therapy is expanding rapidly as the worldwide use 
of DBS is more than 160 000 cases.2 DBS is a generally 
safe procedure but, it is very expensive, potentially a 
dangerous surgical procedure and like any surgical 
procedure comes with some risks as complications.3 
In addition, despite the success of DBS in patients’ 
treatment some key questions remained unanswered 
such as which areas of the brain should be stimulated for 
each patient.2 This letter aims to highlight the merits of 
new DBS technology to create patient-specific solutions 
for treatment of various neurological and psychiatric 
conditions, and this generated great interest in the 
development of new technologies and new education. In 
addition, neurosurgeons, neuroscientist, spine surgeons, 
and researchers are appearing on the letter. 
Up to now, three noninvasive DBS technologies 
have been used in animal studies4,5: (1) Grossman et 
alintroduced a noninvasive DBS method that called 
temporal interference (TI) stimulation. In TI, two low-
frequency waves with a small difference (e.g., 2.0 kHz 
and 2.01 kHz), are inserted transcranially, and the brain 
rectifies the differential signal of very low frequency and 
gets stimulated (Figure 1).4 They represented activation 
of deep neurons in the mice hippocampus while the 
cells placed in the path between stimuli and target was 
not stimulated.4 (2) Zhou et al reported noninvasive 
ultrasound DBS (U-DBS) for the treatment of PD in a 
mice model. They showed that the U-DBS stimulation 
of the subthalamic nucleus (STN) or the globus pallidus 
(GP) could improve the motor behavior of a PD mice 
model.5 In this study the nucleus stimulation was 
performed with spatial resolution up to millimeter, 
the safety of ultrasound stimulation was distinguished 
and no hemorrhage or tissue damage was detected.5 In 
addition, a wearable head-mounted ultrasound array 
transducer was designed to precisely focus on the deep 
nucleus of mouse brain (Figure 2).5 (3) Additionally, 
Chen et al have developed an approach to non-invasively 
manipulate optogenetically the modified nerve cells in 
deep structures inside the brain in live mouse models. In 
this work a near-infrared (NIR) light was placed above the 
skull. It is known that NIR rays can simply pass through 
the brain tissue with a negligible scattering and reach the 
deep within the brain. Optogenetical activation of the 
modified neurons was performed by embedding the up-
conversion nano-particles (UCNPs; blue) in the brain to 
absorb the NIR light and emit a visible light of specific 
wave length (Figure 3).6 
Let’s look closer and find out why noninvasive DBS 
technology is needed. It is believed that, in noninvasive 
DBS technologies, multiple deep brain targets can be 
stimulated simultaneously,4,6 to optimize the treatment 
of patients with CNS disorders. Nevertheless, recent 
(failed) clinical trials of I-DBS in depression, and modest 
treatment results in dementia and epilepsy, encourage 
their further development.1 Although, understanding 
of how I-DBS works has progressed over the past two 
decades, however there is still much to be learned. For the 
time being, noninvasive DBS technology is needed for a 
variety of reasons, such as to assess the best DBS target, 
to identify brain circuits involved in CNS disorders, 
growing understanding of the mechanisms involved, 
better performance evaluation DBS systems, find new 
therapeutic targets, increasing accuracy in treatment, 
optimal patient selection and the appropriate target 
location according to the patient age and cognitive status, 
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and reduce the research costs. Now, the crucial question 
is: which of the three noninvasive DBS technologies is 
a selected candidate for achieving the listed goals and it 
works well in the clinical practice? as it will answer in 
the future. Overall, we suppose that further practicing 
the noninvasive DBS in treatment of neurological and 
psychiatric disorders could provide new treatment 
options and expand current knowledge.
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Figure 1. Noninvasive DBS method that called temporal 
interference (TI) stimulation. Figure reproduced with the 
permission of Grossman et al.4
Figure 2. Noninvasive Ultrasound Deep Brain Stimulation. 
(a) Timeline of the experiment; 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine was administrated from day 1 to 5 and U-DBS 
stimulation was delivered from day 6 to 12. Rotarod test was 
assessed on day 6, 9, and 12. Pole test was done on day 6 and 12, 
and the open field test was conducted on day 12. (b)The wearable 
ultrasound for deep brain stimulation of the STN (c) or GP (d). 
Figure reprinted with the permission of Zhou et al.5
Figure 3. Noninvasive deep brain stimulation with 
Optogenetics. Figure reproduced with the permission of Chen 
et al.6
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